Med. praxi. 2014;11(4):175-179

Muscle relaxants in acute low back pain therapy

MUDr.Michal Prokeš, PharmDr.Josef Suchopár
INFOPHARM a. s., Praha

Centrally acting muscle relaxants (myorelaxants) are widely used to treat patiens with low back pain (VAS). This article describes basic

approach of general practitioner to a patient with VAS, the position of myorelaxants in VAS guidelines and points out the adverse effects

of these drugs. Although myorelaxants are widely prescribed, there are only few clinical trials with proper methodologic design, which can

prove the effectiveness of these drugs for the VAS treatment. The appropriate indication and choice of the muscle relaxant shoud be considered

individually and the decision should be made with respect to side-effects profile, patient preferences and possible drug interactions.

Keywords: muscle relaxants, low back pain, adverse drug reactions, drug interactions

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prokeš M, Suchopár J. Muscle relaxants in acute low back pain therapy. Med. praxi. 2014;11(4):175-179.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Manek NJ, MacGregor AJ. Epidemiology of back disorders: prevalence, risk factors, and prognosis. Curr Opin Rheumatol 2005; 17(2): 134-140. Go to original source... Go to PubMed...
    2. Casazza BA: Diagnosis and treatment of acute low back pain. Am Fam Physician 2012; 85(4): 343-350. Go to PubMed...
    3. Skála B, Effler J, Herle P, Fiala P. Bolesti zad - vertebrogenní algický syndrom 2011. Doporučení diagnostický a léčebný postup pro všeobecné praktické lékaře. http://www.svl.cz/Files/nastenka/page_4771/Version1/bolesti-zad-2011.pdf.
    4. Mlčoch Z. Vertebrogenní algický syndrom. Medicína pro praxi 2008; 5(11): 437-439, http://www.medicinapropraxi.cz/artkey/med-200811-0009.php.
    5. Kříž V, Majerová V. Vertebrogenní algický syndrom - poruchy cerviko-thorakálního přechodu a jeho vztahy k ostatním úsekům páteře. Medicína po promoci 2010/6 http://www.tribune.cz/clanek/20718-vertebrogenni-algicky-syndrom-poruchy-cerviko-thorakalniho-prechodu-a-jeho-vztahy-k-ostatnim-usekum-patere.
    6. Šléglová O. Farmakoterapie nespecifických bolestí páteře. Prezentace v Powerpointu, volně dostupná na http://cs.gunainternational.com/seminare-fyziologicke-regulacni-mediciny.
    7. Kraus J, Havrdová E. Léčiva používaná k terapii nervosvalových chorob a roztroušené sklerózy, in: Suchopár J et al: Remedia Compendium, Panax 2009; 4: 220-228.
    8. Van Tulder M, Touray T, Furlan AD, et al. Muscle relaxants for nonspecific low back pain: a systematic review within the Framework of the Cochrane Collaboration. Spine 2003; 28: 1978-1992. Go to original source... Go to PubMed...
    9. See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician 2008; 78(3): 365-370. Go to PubMed...
    10. Paarek A, Chandurkar N, Chandanwale AS, et al. Aceclofenac-tizanidin in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J 2009; 18: 1836-1842. Go to original source... Go to PubMed...
    11. Nežádoucí účinky léčiv. Informační zpravodaj, Státní ústav pro kontrolu léčiv. 2013/2, strana 1-2, volně ke stažení na http://www.sukl.cz/sukl/informacni-zpravodaj-nezadouci-ucinky-leciv-2-2013.
    12. Thomas E, Bellón T, Barranco P, et al. Acute generalized exanthematous pustulosis due to tetrazepam. J Investig Allergol Clin Immunol 2008; 2008: 18(2): 119-122.
    13. Sánchez-Morillas L, Laguna-Martínez JJ, Reano-Martos M, et al: Systemic dermatitis due to tetrazepam. J Investig Allergol Clin Immunol 2008; 2008: 18(5): 404-406.
    14. Swinnen I, Ghys K, Kerre S, et al. Occupational airborne contact dermatidis from benzodiazepines and other drugs. Contact Dermatitis 2014; 70(4): 227-232. Go to original source... Go to PubMed...
    15. Landeck L, Skudlik C, John SM. Airborne contact dermatitis to tetrazepam in geriatric nurses - a report of 10 cases. J Eur Acad Dermatol Venerol 2012; 26(6): 680-684. Go to original source... Go to PubMed...
    16. Vander Hulst K, Kerre S, Goossens A. Occupatinal allergic contact dermatitis from tetrazepam in nurses. Contact Dermatitis 2010; 62(5): 303-308. Go to original source... Go to PubMed...
    17. Breuer K, Worm M, Skudlik C, et al. Occupational airborne contact allergy to tetrazepam in geriatric nurse. J Dtsch Dermatol ges 2009; 7(10): 896-898. Go to original source... Go to PubMed...
    18. Ribi C, Vermeulen C, Hausser C. Anaphylactic reactions to tolperisone (Mydocalm(R)). Swissd Med Wkly 2003; 133: 369-371, www.smw.ch. Go to original source...
    19. Kwaśniewski A, Korbuszewska-Gontarz B, Mika S. Mydocalm causing anaphylaxis. Pneumol Alergol Pol 2003; 71: 250-252.
    20. Kraus J, Havrdová E. Léčiva používaná k terapii nervosvalových chorob a roztroušené sklerózy, in: Remedia Compendium, čtvrté vydání, Panax 2009: 220-230.
    21. Souhrn údajů o přípravku Sirdalud(R) (tizanidin). Novartis s.r.o., 2014, AISLP 2014.2.
    22. Souhrn údajů o přípravku Muscoril(R) (thiokolchikosid). sanofi-aventis, s.r.o., 2014, AISLP 2014.2.
    23. Souhrn údajů o přípravku Dorsiflex(R) (mefenoxalon). Lek, Pharmaceuticals, d.d., 2008, AISLP 2014.2.
    24. Souhrn údajů o přípravku Dimexol(R) (mefenoxalon). Glenmark Pharmaceuticals, s.r.o., 2009, AISLP 2014.2.
    25. Sackett DL, Rosenberg WM, Gray JA, et al.: Evidence based medicine: what i tis and what it isn´t. BMJ 1996; 312(7023): 71-72 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2349778/. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.